Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Obesity Linked With Improved Survival in mCRPC

Radium-223 Use in mCRPC Differs By Race

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

Newer mCRPC Drugs Led to Longer Survival in African American Patients

Hyperkalemia Worsens Outcomes in Elderly Patients Hospitalized for HF

Low Carb Diet + Walking May Ease ADT's Adverse Effects

Spironolactone Has No Effect on LVM in Hemodialysis Patients

Study: Dialysis Is a Bigger Mortality Risk Than Some Cancers